U.S. sanctions on Chinese companies operating in Xinjiang or with the Chinese military have reshaped supply chains from agriculture to technology. It’s a different story for the pharmaceutical industry.  For multinational drugmakers with R&D investments and human trials running at Chinese hospitals, there is no regulation prohibiting drug development or clinical testing in a region otherwise subject to a range of existing U.S. sanctions and restrictions. Data put together by The